255 results about "Viral antigens" patented technology

The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. The invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.

The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a polymeric nanoparticle containing a vaccine comprising a fusion peptide or a modified peptide. Such a fusion peptide is composed of an insertion signal sequence and a peptide derived from a tumor antigen or a viral antigen, which improves antigen presentation and induces CTL with higher efficiency against cancer cells and virus-infected cells. An exemplary peptide utilized in the invention is Mart-1:27-35 peptide.

Improved molecular vaccines comprise nucleic acid vectors that encode a fusion polypeptide that includes polypeptide or peptide physically linked to an antigen. The linked polypeptide is one that (a) promotes processing of the expressed fusion polypeptide via the MHC class I pathway and/or (b) promotes development or activity of antigen presenting cells, primarily dendritic cells. These vaccines employ one of several types of nucleic acid vectors, each with its own relative advantages: naked DNA plasmids, self-replicating RNA replicons and suicidal DNA-based on viral RNA replicons. Administration of such a vaccine results in enhance immune responses, primarily those mediated by CD8+ cytotoxic T lymphocytes, directed against the immunizing antigen part of the fusion polypeptide. Such vaccines are useful against tumor antigens, viral antigens and antigens of other pathogenic microorganisms and can be used in the prevention or treatment of diseases that include cancer and infections.

Genetic vaccines and methods are provided for enhancing the immunity of a host such as a human to one or more pathogens. In one aspect, a method of enhancing the immunity of a host to a pathogen is provided. The method comprises administering to the host a recombinant virus comprising an antigen sequence that is heterologous to a native progenitor of the recombinant adenovirus and encodes a viral antigen from a pathogenic virus, expression of which is under the transcriptional control of a first promoter; and a cytokine sequence that is heterologous to the native progenitor of the recombinant adenovirus and encodes a cytokine, expression of which is under the transcriptional control of a second promoter. Expression of the antigen and cytokine sequences elicits an immune response directed against the viral antigen upon infection of the host by the recombinant virus. The method can be used for immunizing a host against a wide variety of pathogen viruses, such as HIV, Ebola virus, Marburg virus, hepatitis B virus, hepatitis C virus, influenza virus, human simplex virus, human papilloma virus and respiratory syncytial virus.

The invention seeks to avoid components in split vaccines that could cause an excessive Th2 response. Thus the invention provides an immunogenic composition comprising a split influenza virus antigen and a Th1 adjuvant, wherein the antigen is preferably prepared from a virus grown in cell culture (e.g., it is free from egg proteins).

The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.

The present invention provides a method and device for conducting a rapid in vitro enzyme immunoassay test for the direct and qualitative detection of two or more viral antigens from specimens of symptomatic patients. The method for immunoassay of viral antigens is performed on a membrane. Non-immunological capture of viral antigens takes place by absorption onto the membrane. Captured antigen binds to a detection reagent that includes a label conjugated to a specific antibody. The test is a differentiated test such that two or more viral antigens may be distinguished from each other in a single test. The invention also includes a kit for performing an assay in accordance with the method of the present invention, wherein the kit comprises the device of the present invention.

The invention relates to a kind of hydrophobia vaccine for human, which in detail relates to a freeze-drying hydrophobia vaccine for human and its preparation method. It is contained in physiological soluble buffer solution with pH being 7-8, the sodium chloride weight proportion is 0.4-1.0%, one or several from mycose, sucrose, gelatin, maltose and dextran is used as stabilizing agent, the concentration is 0.5-5%; the weight proportion of shaping agent for freeze-drying agent is 1-5%, and the purified hydrophobia viral antigen concentration is 4-20 IU per ml.

The present invention is directed to mammalian T cells and methods for using these T cells. More specifically, the invention relates to viral specific T cells that express an endogenous viral antigen receptor, a chimeric anti-tumor receptor and the chemokine receptor CCR7. These T cells are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases and that are able to traffic to lymph nodes and sites of minimal residual disease.

The invention discloses an affinity absorption column for specially removing virions from blood and preparing method thereof, in particular relates to an affinity absorption column for blood purification. The affinity absorption column comprises an absorption carrier, an activator and antivirus surface protein antibody; the activator is added into the absorption carrier to obtain an activated carrier; the antivirus surface protein antibody is added into the activated carrier to perform antibody coupling to obtain an immune absorber, and the immune absorber is loaded into the absorption column to obtain the affinity absorption column. The affinity absorption column has the advantages of strong specificity, little toxic side effect, good therapeutic effect, good repeatability and low cost, and is suitable for blood purification; besides, being a separation technology, the affinity absorption column can be widely applied to other fields for the purification and separation of virus antibodies.

Microparticles with absorbed polypeptide-containing molecules formed without the use of surfactant, methods of making such microparticle compositions, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like. Preferred polymers are poly(D,L-lactide-co-glycolides), more preferable those having a lactide/glycolide molar ratio ranging from 40:60 to 60:40 and having a molecular weight ranging from 20,000 Daltons to 70,000 Daltons. Preferred polypeptide containing molecules are bacterial and viral antigens (including HIV antigens, meningitis B antigens, streptococcus B antigens, and Influenza A hemagglutinin antigens).

The invention relates to a colloidal gold immunochromatography test strip for simultaneously detecting viral antigens and antibodies. The test strip comprises a first glue strip and a second glue strip which are arranged in parallel, wherein the first glue strip comprises a first sample pad, a first conjugate pad, a first nitrocellulose membrane and first absorbent paper, which are sequentially lapped with one another, the first conjugate pad is coated with colloidal gold marked by the viral antigens, the first nitrocellulose membrane is coated with viral antibodies and antibodies, the viral antibodies are taken as a first detection line, and the antibodies are used for resisting the viral antigens on the colloidal gold and are taken as a quality control line; the second glue strip comprises a second sample pad, a second conjugate pad, a second nitrocellulose membrane and second absorbent paper, which are sequentially lapped with one another, the second conjugate pad is coated with the colloidal gold marked by the viral antigens, the second nitrocellulose membrane is coated with anti-human IgG antibodies and anti-human IgM antibodies, the anti-human IgG antibodies are taken as a second detection line, and the anti-human IgM antibodies are taken as a third detection line. The colloidal gold immunochromatography test strip can be used for simultaneously detecting the viral antigens as well as the IgG antibodies and IgM antibodies of the viral antigens.

The invention belongs to the technical field of biochemical sensing, and discloses a semiconductor sensor for virus detection as well as a preparation method and an application thereof. The preparation method comprises the steps of (1) preparing an oxide or chalcogenide colloid semiconductor nano-material; (2) coating the surface of the colloid semiconductor nano material with a virus specific antigen or antibody to obtain a sensitive material; and (3) based on the sensitive material, preparing the virus detection sensor by adopting device structures such as a chemically modified electrode ora field effect transistor. The virus specific antigen or antibody is introduced to the surface of the colloid semiconductor nano material, charge transfer caused by a specific binding reaction betweenthe virus antigen and antibody is converted into a sensor electric signal to be output through a semiconductor sensitive effect, and the real-time performance and convenience of a virus detection technology are improved.

The invention relates to a polymer lipid nanoparticle, a preparation method and application thereof as a vaccine adjuvant system. The polymer nanoparticle is a solid sphere composed of a macromoleclar polymer, positively charged cationic lipid is inlaid on the surface, the nanoparticle surface can adsorb protein antigen, polypeptide antigen, viral antigen and other active drugs; the polymer nanoparticle has an average particle size of less than 300nm, a dispersion coefficient, i.e. a PDI (polydispersity) value of less than 0.2, and a Zeta potential average value of greater than 20mV. The polymer nanoparticle provided by the invention has the characteristics of uniform size, high antigen carrying rate, and good maintenance of antigen activity, when the polymer nanoparticle carries an antigen and serves as a vaccine adjuvant, the intake of antigen presenting cells (APCs) to the antigen can be increased, the activation level of antigen presenting cells is improved, and the follow-up immune response level is strengthened.